| Project/Area Number |
20592025
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
OTA Ichiro Nara Medical University, 医学部, 助教 (00326323)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YANE Katsunari 近畿大学, 医学部, 教授 (40220199)
AKAHASHI Akihisa 群馬大学, 先端科学研究指導者育成ユニット, 准教授 (60275336)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | 頭頸部がん / 放射線治療 / 抗がん剤 / mTOR / p53 / アポトーシス / 放射線 |
|---|
| Research Abstract |
A high extent of activation of the PI3K/Akt pathway is involved in head and neck cancer therapeutic resistance, including radiotherapy and chemotherapy. The aim of this study was to examine whether the effect of rapamycin, an inhibitor of mTOR, on chemo- and radio-sensitivity is affected in human head and neck cancer cells. Rapamycin could enhance the effect of radiation and cisplatin through the repression of pro-survival signals, including PI3K/Akt pathway, and the reduction in the apoptotic threshold.
|
